ArGEN-X BV has secured a collaboration with Bayer AG to discover and develop candidate therapeutic antibodies directed at a number of targets across multiple therapeutic areas that, it says, are often intractable to existing antibody platforms. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
